LLY vs. ABBV
Compare and contrast key facts about Eli Lilly and Company (LLY) and AbbVie Inc. (ABBV).
Performance
LLY vs. ABBV - Performance Comparison
Loading graphics...
LLY vs. ABBV - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
LLY Eli Lilly and Company | -14.27% | 40.25% | 33.30% | 60.91% | 34.26% | 66.08% | 31.04% | 16.14% | 40.45% | 17.83% |
ABBV AbbVie Inc. | -4.05% | 33.08% | 18.86% | -0.23% | 24.01% | 32.43% | 27.72% | 1.47% | -0.96% | 60.07% |
Fundamentals
LLY:
$825.96B
ABBV:
$385.83B
LLY:
$22.96
ABBV:
$2.38
LLY:
40.06
ABBV:
91.23
LLY:
12.68
ABBV:
6.30
LLY:
$65.18B
ABBV:
$61.16B
LLY:
$54.62B
ABBV:
$44.85B
LLY:
$27.94B
ABBV:
$28.29B
Returns By Period
In the year-to-date period, LLY achieves a -14.27% return, which is significantly lower than ABBV's -4.05% return. Over the past 10 years, LLY has outperformed ABBV with an annualized return of 30.92%, while ABBV has yielded a comparatively lower 19.07% annualized return.
LLY
- 1D
- 3.74%
- 1M
- -12.57%
- YTD
- -14.27%
- 6M
- 20.93%
- 1Y
- 12.19%
- 3Y*
- 39.90%
- 5Y*
- 39.16%
- 10Y*
- 30.92%
ABBV
- 1D
- 2.05%
- 1M
- -6.29%
- YTD
- -4.05%
- 6M
- -4.63%
- 1Y
- 7.29%
- 3Y*
- 15.00%
- 5Y*
- 19.40%
- 10Y*
- 19.07%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
LLY vs. ABBV — Risk / Return Rank
LLY
ABBV
LLY vs. ABBV - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Eli Lilly and Company (LLY) and AbbVie Inc. (ABBV). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| LLY | ABBV | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 0.29 | 0.27 | +0.02 |
Sortino ratioReturn per unit of downside risk | 0.69 | 0.54 | +0.15 |
Omega ratioGain probability vs. loss probability | 1.10 | 1.07 | +0.02 |
Calmar ratioReturn relative to maximum drawdown | 0.42 | 0.53 | -0.11 |
Martin ratioReturn relative to average drawdown | 1.02 | 1.17 | -0.15 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| LLY | ABBV | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 0.29 | 0.27 | +0.02 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 1.23 | 0.86 | +0.36 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 1.04 | 0.74 | +0.30 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.56 | 0.74 | -0.18 |
Correlation
The correlation between LLY and ABBV is 0.41, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.
Dividends
LLY vs. ABBV - Dividend Comparison
LLY's dividend yield for the trailing twelve months is around 0.68%, less than ABBV's 3.06% yield.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
LLY Eli Lilly and Company | 0.68% | 0.56% | 0.67% | 0.78% | 1.07% | 1.23% | 1.75% | 1.96% | 1.94% | 2.46% | 2.77% | 2.37% |
ABBV AbbVie Inc. | 3.06% | 2.87% | 3.49% | 3.82% | 3.49% | 3.84% | 4.41% | 4.83% | 3.89% | 2.65% | 3.64% | 3.41% |
Drawdowns
LLY vs. ABBV - Drawdown Comparison
The maximum LLY drawdown since its inception was -68.24%, which is greater than ABBV's maximum drawdown of -45.09%. Use the drawdown chart below to compare losses from any high point for LLY and ABBV.
Loading graphics...
Drawdown Indicators
| LLY | ABBV | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -68.24% | -45.09% | -23.15% |
Max Drawdown (1Y)Largest decline over 1 year | -30.26% | -16.74% | -13.52% |
Max Drawdown (5Y)Largest decline over 5 years | -34.48% | -21.92% | -12.56% |
Max Drawdown (10Y)Largest decline over 10 years | -34.48% | -45.09% | +10.61% |
Current DrawdownCurrent decline from peak | -17.00% | -9.64% | -7.36% |
Average DrawdownAverage peak-to-trough decline | -19.25% | -10.70% | -8.55% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 12.39% | 8.12% | +4.27% |
Volatility
LLY vs. ABBV - Volatility Comparison
Eli Lilly and Company (LLY) has a higher volatility of 9.04% compared to AbbVie Inc. (ABBV) at 7.57%. This indicates that LLY's price experiences larger fluctuations and is considered to be riskier than ABBV based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| LLY | ABBV | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 9.04% | 7.57% | +1.47% |
Volatility (6M)Calculated over the trailing 6-month period | 26.21% | 19.03% | +7.18% |
Volatility (1Y)Calculated over the trailing 1-year period | 42.44% | 27.12% | +15.32% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 32.14% | 22.61% | +9.53% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 29.80% | 25.71% | +4.09% |
Financials
LLY vs. ABBV - Financials Comparison
This section allows you to compare key financial metrics between Eli Lilly and Company and AbbVie Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
LLY vs. ABBV - Profitability Comparison
LLY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Eli Lilly and Company reported a gross profit of 16.41B and revenue of 19.29B. Therefore, the gross margin over that period was 85.1%.
ABBV - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, AbbVie Inc. reported a gross profit of 13.96B and revenue of 16.62B. Therefore, the gross margin over that period was 84.0%.
LLY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Eli Lilly and Company reported an operating income of 8.78B and revenue of 19.29B, resulting in an operating margin of 45.5%.
ABBV - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, AbbVie Inc. reported an operating income of 5.81B and revenue of 16.62B, resulting in an operating margin of 35.0%.
LLY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Eli Lilly and Company reported a net income of 6.64B and revenue of 19.29B, resulting in a net margin of 34.4%.
ABBV - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, AbbVie Inc. reported a net income of 1.82B and revenue of 16.62B, resulting in a net margin of 10.9%.